Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Learn which fund family offers the best Sharpe ratio indices and why it matters for risk-adjusted performance. Compare funds to identify strong performers.
28,055 articlesLilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Roughly 200M XRP moved off Binance in the last 10 days, signaling possible accumulation as XRP trades around $1.42.
Tally, a leading DAO governance tool used by hundreds of communities, will shut down after five years as regulators c...
Palantir has a large revenue backlog, a major Army contract on the books, and ambitious growth guidance. This analysi...
Two tobacco giants show divergent paths over 10 years, with dividend income boosting returns for both. Here's what ha...
When Warren Buffett's successor Greg Abel took the helm, Berkshire Hathaway signaled a new phase. This article breaks...
As the AI arms race accelerates, Microsoft leans on Copilot to reverse signals of lost momentum. Early traction and p...
Two decades after its IPO, Mastercard has delivered a remarkable gain of about 11,000%, cementing its place among the...
Snowflake stock soaring has investors buzzing. This guide explains what's driving the rally, how to value the stock, ...
A trader alleges Polymarket unfairly resolved a market tied to MicroStrategy's bitcoin sale, claiming a post-deadline...
Microsoft faces a landmark decision as its OpenAI stake fuels an expanding AI push. The company must balance monetizi...